Abstract:PurposeThe effect of adjuvant irradiation after mastectomy in early-stage breast cancer patients remains controversial. The present study aims to explore the clinical benefit obtained from adjuvant radiotherapy among post-mastectomy pT1-2N1 breast cancer patients who received adjuvant modern systemic therapy.MethodsMedical records of consecutive patients with pT1-2N1 breast cancer who received mastectomy in our institution between January 2009 and December 2016 were retrospectively reviewed. High-risk features consist of patient age, number of positive lymph nodes, T stage, and Ki67 index, which were developed previously at our institution using early-stage breast cancer patients after mastectomy without adjuvant radiotherapy. Differences of survival and local recurrence were compared between no-postmastectomy radiotherapy (PMRT) and PMRT group according to number of risk factors. The time-to-event curves were calculated by the Kaplan–Meier methods and compared by the log-rank test. Propensity score matching (PSM) was performed to reduce the imbalances in patient characteristics.ResultsA total of 548 patients were enrolled (no-PMRT: 259 and PMRT: 289). After a median follow-up of 69 months, the 5-year rate of DFS, BCSS, and LRR in the overall cohort was 90.2%, 97.4%, and 3.6%, respectively. PMRT did not significantly improve DFS, BCSS, and LRRFS in the whole cohort. Patients were divided into low-risk (with no or one risk factor) and high-risk (with two or more risk factors) groups. According to the univariable and multivariable analysis, high-risk group (HR = 1.81, 95% CI 1.11–2.98, p = 0.02) was demonstrated as an independent risk factor for DFS. For the high-risk group, PMRT significantly improved DFS from 81.4% to 91.9% and BCSS from 95.5% to 98.6% and decreased the 5-year rate of LRR from 5.6% to 1.4%, respectively (p < 0.01, p = 0.05, and p = 0.06). However, no survival benefit from PMRT was observed in the low-risk group in terms of DFS, BCSS, and LRR (p = 0.45, p = 0.51, and p = 0.99, respectively). In multivariate analysis, PMRT remained an independent prognostic factor for DFS (HR = 0.50, 95% CI 0.24–1.00, p = 0.05) in the high-risk group. After PSM analysis, the survival benefit of PMRT was sustained in high-risk patients.ConclusionPMRT significantly improved DFS in high-risk pT1-2N1 breast cancer patients, but not in low-risk patients. Independent validation of our scoring system is recommended.

Postmastectomy Radiotherapy in Patients with T 1-2 N 1 Breast Cancer: a Single Center Experience and a Meta-Analysis

Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT1-2N+ Breast Cancer Patients: A Single Center Experience and Review of Current Literature

Real-world Impact of Postmastectomy Radiotherapy in T1–2 Breast Cancer with One to Three Positive Lymph Nodes

Postmastectomy Radiation Therapy Does Not Improve Outcome for Pathologic T3N0 Breast Cancers

Post-Mastectomy Radiotherapy For Breast Cancer Patients With T1-T2 And 1-3 Positive Lymph Nodes: A Meta-Analysis

Outcomes with and without postmastectomy radiotherapy for pT3N0‐1M0 breast cancer: An institutional experience

T1-2N1M0 Triple-Negative Breast Cancer Patients from the SEER Database Showed Potential Benefit from Post-Mastectomy Radiotherapy.

The Prognostic Differences and the Effect of Postmastectomy Radiotherapy Between Post‐chemotherapy Ypt1‐2ypn1 and De Novo Pt1‐2n1 Breast Cancer

Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy

The Impact of Postmastectomy Radiotherapy on Ct1-2N1 Breast Cancer Patients with Ypn0 after Neoadjuvant Chemotherapy: a Retrospective Study Based on Real-World Data

Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes

Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.

Postmastectomy Radiotherapy Improves Survival Benefits in De Novo Stage IV Breast Cancer: A Propensity-Score Matched Analysis

Meta-analysis on survival rate after post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes

Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer.

Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?

Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer with Modern Systemic Therapy

Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy

Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers

Postmastectomy Radiation Therapy and Survival Outcome in Older Patients with T1-2N1 Breast Cancer

Post-mastectomy Radiotherapy Can Improve Survival in Breast Cancer Patients Aged 35 Years or Younger with Four or More Positive Nodes but Not in One to Three Positive Nodes